Hok Pan Yuen

List of Publications by Year
in descending order

25 papers	4,834 citations	471509 17 h-index	580821 25 g-index
27 all docs	27 docs citations	27 times ranked	3291 citing authors

#	Article	IF	Citations
1	Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand Journal of Psychiatry, 2005, 39, 964-971.	2.3	1,677
2	Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research, 2003, 60, 21-32.	2.0	981
3	Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research, 2004, 67, 131-142.	2.0	673
4	Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?. Schizophrenia Bulletin, 2007, 33, 673-681.	4.3	376
5	Long-term Follow-up of a Group at Ultra High Risk ("Prodromal") for Psychosis. JAMA Psychiatry, 2013, 70, 793.	11.0	373
6	Effect of Ï‰-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.	11.0	216
7	Declining transition rates to psychotic disorder in "ultra-high risk" clients: Investigation of a dilution effect. Schizophrenia Research, 2016, 170, 130-136.	2.0	87
8	NEURAPRO study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Microbial Biotechnology, 2017, 11, 418-428.	1.7	55
9	Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Microbial Biotechnology, 2018, 12, 292-306.	1.7	52
10	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2019, 206, 67-74.	2.0	46
11	Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. Schizophrenia Bulletin Open, 2020, 1, .	1.7	45
12	Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study. Neuropsychopharmacology, 2021, 46, 1494-1501.	5.4	44
13	Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach. Frontiers in Psychiatry, 2020, 11, 553578.	2.6	30
14	Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-up. Schizophrenia Bulletin, 2019, 45, 1101-1111.	4.3	27
15	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.	2.0	27
16	Performance of joint modelling of time-to-event data with time-dependent predictors: an assessment based on transition to psychosis data. PeerJ, 2016, 4, e2582.	2.0	25
17	A new method for analysing transition to psychosis: Joint modelling of time‐to‐event outcome with time‐dependent predictors. International Journal of Methods in Psychiatric Research, 2018, 27, .	2.1	19
18	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first‐episode psychosis with low‐risk of self‐harm or aggression. Study protocol and baseline characteristics of participants. Microbial Biotechnology, 2019, 13, 953-960.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Dynamic prediction of transition to psychosis using joint modelling. Schizophrenia Research, 2018, 202, 333-340.	2.0	18
20	Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population. Microbial Biotechnology, 2021, 15, 642-651.	1.7	11
21	Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis. Microbial Biotechnology, 2021, 15, 874-881.	1.7	10
22	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2020, 218, 48-54.	2.0	8
23	Cognitive ability and metabolic physical health in first-episode psychosis. Schizophrenia Research: Cognition, 2021, 24, 100194.	1.3	5
24	Dynamic prediction systems of transition to psychosis using joint modelling: extensions to the base system. Schizophrenia Research, 2020, 216, 207-212.	2.0	3
25	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	2